Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate in the following investor conferences in September:

  • Citi’s 14th Annual Biotech Conference Four Seasons Hotel Boston, Mass. Thursday, September 5, 2019
  • BioCentury 26th Annual NewsMakers in the Biotech Industry Millennium Times Square New York New York, N.Y. Friday, September 6, 2019
  • 3rd Annual Janney Healthcare Conference The Union League Club New York, N.Y. Monday, September 9, 2019 Presentation time: 11:50 a.m. ET

The Janney presentation will be webcast live and archived on the “Investors” section of the Aldeyra website, http://ir.aldeyra.com/.

About Aldeyra Therapeutics Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sj�gren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Corporate Contact: David McMullin Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com

Investor & Media Contact: Scott Solomon Sharon Merrill Associates, Inc. Tel: 617-542-5300 ALDX@investorrelations.com

Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Aldeyra Therapeutics Charts.
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Aldeyra Therapeutics Charts.